Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCleo Diagnostics Ltd

Cleo Diagnostics Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.27 AUD -0.01 ( 3.57%)
Last update at 2026-11-06T04:59:00Z
VOLUME
2493
Market Cap
39.87M

Momentum Score

…

Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.27
Low
0.28
High
52 Week Price Range
0.26
Low
0.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Cleo Diagnostics Ltd (ASX: COV) is limited, and its publicly disclosed materials provide sparse detail on its operations and product pipeline. As a company in medical diagnostics, long-term growth may depend on successful product development, regulatory approvals, commercial partnerships and access to capital, which could support expansion if executed. Investors may find the company attractive if it achieves clinical validation and secures distribution, but these outcomes are uncertain.

The most important investment risks are limited disclosure and transparency, regulatory and execution risk common to diagnostic developers, funding and liquidity constraints, and low trading liquidity on the ASX.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.28
Dividend Yield
-
Revenue TTM
1.72M
Revenue Per Share
0.01
Gross Profit TTM
1.72M
Debt / Equity
-
ROE
-109.48%
Net Debt
1.36M
ROCE
-157.40%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -5.94M -4.00M -3.76M -1.73M -0.04M
Net income -5.94M -4.00M -3.76M -1.73M -0.04M
Selling general administrative 2.49M 2.14M 1.58M 1.39M -
Reconciled depreciation 0.06M - 0.06M 0.04M -
Operating income -7.89M -3.90M -3.61M -1.58M -0.02M
Interest expense - - 0.03M 0.11M -
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.23M 0.00M 0.03M 0.11M 0.00M
Net interest income 0.23M - 0.34M -0.11M -
Total revenue - 1.18M 0.60M 0.11M 0.00M
Total operating expenses - 5.08M - - -
Total other income expense net 1.72M - 0.24M 0.11M -
Net income from continuing ops -5.94M - -3.76M -1.73M -
Net income applicable to common shares - -4.00M -3.76M -1.73M -0.04M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 6.68M 6.94M 9.88M 1.08M 0.24M
Intangible assets 0.31M 0.36M 0.41M 0.46M 0.20M
Total liab 1.67M 1.10M 0.49M 2.02M 0.29M
Total stockholder equity 5.01M 5.83M 9.39M -0.94M -0.04M
Common stock - 13.71M - - 0.00M
Capital stock 18.17M - 13.71M 0.05M -
Retained earnings -15.47M -7.87M -5.53M -1.77M -0.04M
Cash 6.22M 0.75M 9.37M 0.24M 0.04M
Cash and equivalents - 5.71M - - -
Total current liabilities 1.67M 1.10M 0.49M 2.02M 0.29M
Net debt - - - 1.36M -
Short term debt - 0.00M - - 0.24M
Short long term debt - - - 1.60M -
Property plant equipment - 0.03M - - -
Total current assets 6.34M 6.55M 9.44M 0.58M 0.04M
Net receivables - 0.07M 0.06M 0.03M 0.00M
Accounts payable 1.29M - 0.44M 0.42M -
Non current assets total 0.34M - 0.44M 0.50M -
Long term debt total - 0.00M - - 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Type yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Investments - - -0.00M -0.34M
Total cashflows from investing activities - -0.01M -0.00M -0.34M
Total cash from financing activities 4.71M 0.00M 11.17M 1.22M
Net income -5.94M - -3.76M -1.73M
Change in cash -0.24M -2.91M 9.13M 0.20M
Begin period cash flow 6.46M - 0.24M 0.04M
End period cash flow 6.22M - 9.37M 0.24M
Total cash from operating activities - -2.90M -2.03M -0.68M
Issuance of capital stock 5.08M - 12.00M -
Sale purchase of stock -0.37M 0.00M 12.00M 0.00M
Other cashflows from financing activities - 0.00M -0.83M -0.18M
Capital expenditures 0.01M 0.01M 0.00M 0.34M
Change in working capital - 1.15M 0.56M -
Free cash flow -4.95M - -2.03M -1.02M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
COV
Cleo Diagnostics Ltd		 -0.01
3.57%		 0.27 - - 23.22 8.38
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17

Profile*

Cleo Diagnostics Ltd

Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.

480 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9614 0600

https://www.cleodx.com

Name Title Year Born
Dr. Richard Allman Ph.D. CEO & Exec. Director 1960
Dr. Andrew N. Stephens Chief Scientific Officer & Exec. Director NA
Prof. Thomas William Jobling Lead Medical Advisor & Independent Non-Exec. Director NA
Ms. Pauline M. Moffatt AAICD, B.Com., BCom, FGIA Company Sec. NA
Dr. Richard Allman Ph.D. CEO & Exec. Director 1960
Dr. Andrew N. Stephens Chief Scientific Officer & Exec. Director NA
Prof. Thomas William Jobling Lead Medical Advisor & Independent Non-Exec. Director NA
Ms. Pauline M. Moffatt AAICD, B.Com., BCom, FGIA Company Sec. NA
Dr. Richard Allman Ph.D. CEO & Exec. Director 1960
Dr. Andrew N. Stephens Chief Scientific Officer & Exec. Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…